NCT00141739View on ClinicalTrials.gov

Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

August 31, 2011

Study Completion Date

September 30, 2012

Conditions
Graft-Versus-Host Disease
Interventions
DRUG

Etanercept

"Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."

Trial Locations (2)

48109

The University of Michigan, Ann Arbor

60153

Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00141739 - Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) | Biotech Hunter | Biotech Hunter